New opportunities for tailored nanoparticle catalysts through exsolution from inherently disordered defect fluorite-type oxides
Journal of Materials Chemistry A · 2025 · 13 (9) · 6451-6468
DOI: 10.1039/d4ta06854h ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Materials Chemistry A, 2025. Verfasst von William S. J. Skinner und 5 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0). Gefördert von: HORIZON EUROPE Marie Sklodowska-Curie Actions, Engineering and Physical Sciences Research Council.
Abstract (Originalsprache)
Exsolution of Ru nanoparticles from defective fluorite-type Y 2 Zr 2− x Ru x O 7 exhibits exceptional tunability and produces a promising catalyst for the rWGS reaction, achieving near-equilibrium CO 2 conversion and 100% selectivity to CO above 650 °C.
Förderung
- HORIZON EUROPE Marie Sklodowska-Curie Actions
- Engineering and Physical Sciences Research Council
Zitieren
APA
Skinner, W. S. J., Calì, E., Bonis, A. K., Kerherve, G., Kousi, K., & Payne, D. J. (2025). New opportunities for tailored nanoparticle catalysts through exsolution from inherently disordered defect fluorite-type oxides. Journal of Materials Chemistry A, 13(9), 6451-6468. https://doi.org/10.1039/d4ta06854h
Vancouver
Skinner WSJ, Calì E, Bonis AK, Kerherve G, Kousi K, Payne DJ. New opportunities for tailored nanoparticle catalysts through exsolution from inherently disordered defect fluorite-type oxides. Journal of Materials Chemistry A. 2025;13(9):6451-6468. doi:10.1039/d4ta06854h
BibTeX
@article{Skinner2025,
author = {Skinner, William S. J. and Calì, Eleonora and Bonis, Angelos K. and Kerherve, Gwilherm and Kousi, Kalliopi and Payne, David J.},
title = {New opportunities for tailored nanoparticle catalysts through exsolution from inherently disordered defect fluorite-type oxides},
journal = {Journal of Materials Chemistry A},
year = {2025},
volume = {13},
number = {9},
pages = {6451--6468},
doi = {10.1039/d4ta06854h}
}
EUVIMED